ロード中...
Carbamylated Erythropoietin Outperforms Erythropoietin in the Treatment of AKI-on-CKD and Other AKI Models
Erythropoietin (EPO) may be a beneficial tissue–protective cytokine. However, high doses of EPO are associate with adverse effects, including thrombosis, tumor growth, and hypertension. Carbamylated erythropoietin (CEPO) lacks both erythropoietic and vasoconstrictive actions. In this study, we compa...
保存先:
| 出版年: | J Am Soc Nephrol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Nephrology
2016
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5084891/ https://ncbi.nlm.nih.gov/pubmed/26984884 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2015091059 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|